Trials are testing new ways to exploit pancreatic cancer biology. The APOLLO study is evaluating olaparib maintenance in BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →-mutated disease after definitive therapy. Setidegrasib is being added to FOLFIRINOX or NALIRIFOX in a phase 3 trial. BMS-986504 targets MTAP-deleted pancreatic cancers, and HRS-4642 is being studied as conversion therapy in locally advanced disease. ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → strategies include AGEN1423 with botensilimab, durvalumab or adebrelimab added to chemoradiation, oncolytic adenovirus plus programmed death-ligand 1 (PD-L1) targeted radioimmunotherapy, and pembrolizumab added to olaparib. Other approaches include focal adhesion kinase (FAK) and RAF/MEK inhibition with stereotactic body radiotherapy, palbociclib plus binimetinib in RAS-mutant disease, the interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor emavusertib with standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →, and DNA-dependent protein kinase inhibition with peposertib alongside radiotherapy. Earlier-detection work includes fibroblast activation protein inhibitor (FAPI) based positron emission tomography imaging and mechanical profiling of biopsy specimens.
Where the evidence stands
The backbone regimens FOLFIRINOX and gemcitabine plus nab-paclitaxel are supported by large phase 3 trials, and NALIRIFOX has phase 3 evidence in metastatic disease. BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →-targeted olaparib maintenance has phase 3 support in metastatic disease. Most other strategies are in phase 1 or 2. ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → has generally underperformed in pancreatic cancer outside of the small MSI-H subgroup, and stromal-targeted approaches have a mixed track record, so newer immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → and stroma-focused combinations will need careful confirmatory studies. Much preclinical work is exploring ferroptosis, KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →-targeted therapiesDrugs that block specific molecules that cancer cells need to grow.Click for full explanation →, and tumour microenvironment modulation.
What this means for people affected
Pancreatic cancer remains difficult, and early detection in high-risk groups, for example people with a strong family history or known genetic syndromes, is one of the most valuable tools available. For people already diagnosed, genomic testing for BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, NTRK fusions, KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →mutationA change in DNA sequence that can drive cancer development.Click for full explanation → type, MSI, and MTAP deletion can identify the minority who may benefit from targeted therapyDrugs that block specific molecules that cancer cells need to grow.Click for full explanation →. Combination chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → regimens have improved outcomes over gemcitabine alone, but progress has been slow overall, and many new strategies are in early testing. Clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → participation is often discussed because the standard options remain limited.
Last updated April 22, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
ReviewSummary and analysis of existing published studies.Published: April 20, 2026
Understanding a new way to fight pancreatic cancer
Researchers studied how a type of cell death called necroptosis affects pancreatic cancer. They found that it can be triggered by certain chemicals and may help or harm the cancer, depending on the situation. They also identified potential targets for new treatments.
Why it matters: This finding could lead to new approaches for managing pancreatic cancer, a highly lethal disease.
The study is a review of existing research, and the findings are based on previous lab experiments and observations.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 17, 2026
Pancreatic Cancer Linked to High Blood Sugar Levels
Researchers analyzed data from 204 countries to understand how high fasting plasma glucose contributes to pancreatic cancer. They found that high blood sugar levels are linked to a significant number of pancreatic cancer deaths and disability-adjusted life years, with the burden increasing over the past three decades.
Why it matters: This study highlights the importance of managing high blood sugar levels to reduce the risk of pancreatic cancer.
PreclinicalLab or cell studies. No human data yet.Est. completion: January 6, 2028
Screening for Pancreatic Cancer in People at High Risk
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a screening method for pancreatic cancer in people who are at high risk of developing the disease. The trial is currently recruiting participants. The goal is to see if the screening method can detect pancreatic cancer early.
Why it matters: Early detection of pancreatic cancer may improve treatment outcomes for people at high risk.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 16, 2026
New Approach Targets Cancer Stem Cells in Pancreatic Cancer
Researchers developed a new way to target cancer stem cells in pancreatic cancer using a special peptide delivered by tiny particles. This approach may help stop the spread of cancer and make existing treatments more effective. However, more research is needed to confirm these findings.
Why it matters: This finding could lead to new treatments for pancreatic cancer, a highly aggressive and metastatic disease.
Preclinical study, results may not translate to humans.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Est. completion: March 9, 2027
Testing a Combination Treatment for Unresectable Pancreatic Cancer
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a combination of medications, including Gemcitabine and Nab-Paclitaxel, along with Bosentan, to treat pancreatic cancer that cannot be removed by surgery. The trial is currently recruiting participants. The goal is to assess the safety and effectiveness of this treatment combination.
Why it matters: This trial may help researchers better understand how to treat unresectable pancreatic cancer, a serious and often difficult-to-treat condition.
Recruiting participants, early-stage trial with limited data available.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 16, 2026
Rare autoimmune disease mimics pancreatic cancer
Researchers reported a case of a 62-year-old man with a rare autoimmune disease called granulomatosis with polyangiitis (GPA) that presented as a pancreatic mass, leading to a misdiagnosis of cancer. The patient received chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → before a correct diagnosis was made. The researchers highlighted the importance of considering GPA as a differential diagnosis in patients with systemic features and pancreatic lesions.
Why it matters: This finding matters because it highlights the need for accurate diagnosis and the potential for unnecessary treatments in patients with rare autoimmune diseases.
A single case report with fewer than 15 similar cases in the literature.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 15, 2026
KRASG12R pancreatic cancer shows unique vulnerabilities
Researchers studied pancreatic cancer with a rare KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →mutationA change in DNA sequence that can drive cancer development.Click for full explanation → called KRASG12R. They found that this type of cancer behaves differently than others with the same mutationA change in DNA sequence that can drive cancer development.Click for full explanation →, and may be more sensitive to certain treatments. Lab experiments and mouse models helped clarify how KRASG12R promotes cancer growth and why it might be more treatable.
Why it matters: This finding could lead to more targeted treatments for pancreatic cancer patients with the KRASG12R mutationA change in DNA sequence that can drive cancer development.Click for full explanation →.
These studies were conducted in lab experiments and mouse models, and more research is needed to confirm these findings in humans.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: April 1, 2030
High Dose Radiation Therapy for Pancreatic Cancer
Researchers are studying high dose radiation therapy for people with locally advanced pancreatic cancer who initially responded to chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. This trial aims to learn more about the effectiveness of this treatment. The trial is currently recruiting participants.
Why it matters: This trial may help doctors understand if high dose radiation therapy can be a useful treatment option for people with locally advanced pancreatic cancer.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Est. completion: December 31, 2026
Testing XNW28012 for Advanced Solid Tumors
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the safety and effects of XNW28012 in people with advanced solid tumors who have not responded to standard treatments. The trial is currently recruiting participants. The results of this trial are not yet available.
Why it matters: This trial may help researchers understand if XNW28012 is a potential treatment option for people with advanced solid tumors.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: October 1, 2031
Evaluating a New Treatment for Pancreatic Cancer
Researchers are studying a new treatment called BMS-986504 for people with a specific type of pancreatic cancer. The trial is currently recruiting participants. The goal is to see if this treatment is safe and effective.
Why it matters: This trial could help find a more effective treatment for people with MTAP-deleted pancreatic cancer.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 14, 2026
Pancreatic Cancer Models in Lab Experiments
Researchers created lab models of pancreatic cancer from patient samples and tested how different conditions affect their growth and response to chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. They found that the models' behavior was similar to the original tumors, but with some differences. The study suggests that 3D models may be more realistic, but more research is needed.
Why it matters: This study helps us understand how to create more accurate lab models of pancreatic cancer, which could lead to better treatments in the future.
PreclinicalLab or cell studies. No human data yet.Est. completion: May 1, 2030
Pancreatic Cancer Specimens Being Studied with Artidis Nanomechanical Signature Profiling
Researchers are using the Artidis ART-1 Device to analyze pancreatic cancer specimens. This trial is currently recruiting participants. The goal is to understand the potential of this device in identifying characteristics of pancreatic cancer.
Why it matters: This trial may help scientists better understand pancreatic cancer and potentially lead to improved diagnostic tools.
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, BRCA2Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation → or PALB2 MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Treatment
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX ChemotherapiesDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →, in People With Pancreatic Cancer
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study
